- Home
- EXAS vs FHN Comparison
EXAS vs FHN Comparison
Compare EXAS & FHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- FHN
- Stock Information
- Founded
- EXAS 1995
- FHN 1864
- Country
- EXAS United States
- FHN United States
- Employees
- EXAS N/A
- FHN N/A
- Industry
- EXAS Medical Specialities
- FHN Major Banks
- Sector
- EXAS Health Care
- FHN Finance
- Exchange
- EXAS Nasdaq
- FHN Nasdaq
- Market Cap
- EXAS 11.6B
- FHN 10.4B
- IPO Year
- EXAS N/A
- FHN N/A
- Fundamental
- Price
- EXAS $59.25
- FHN $20.11
- Analyst Decision
- EXAS Strong Buy
- FHN Buy
- Analyst Count
- EXAS 16
- FHN 14
- Target Price
- EXAS $72.80
- FHN $20.00
- AVG Volume (30 Days)
- EXAS 2.2M
- FHN 5.3M
- Earning Date
- EXAS 11-05-2024
- FHN 01-16-2025
- Dividend Yield
- EXAS N/A
- FHN 3.02%
- EPS Growth
- EXAS N/A
- FHN N/A
- EPS
- EXAS N/A
- FHN 1.37
- Revenue
- EXAS $2,692,328,000.00
- FHN $3,071,000,000.00
- Revenue This Year
- EXAS $11.81
- FHN N/A
- Revenue Next Year
- EXAS $11.41
- FHN $2.14
- P/E Ratio
- EXAS N/A
- FHN $14.52
- Revenue Growth
- EXAS 11.91
- FHN 0.03
- 52 Week Low
- EXAS $40.62
- FHN $12.95
- 52 Week High
- EXAS $79.62
- FHN $21.72
- Technical
- Relative Strength Index (RSI)
- EXAS 48.86
- FHN 49.87
- Support Level
- EXAS $61.28
- FHN $19.75
- Resistance Level
- EXAS $62.15
- FHN $20.88
- Average True Range (ATR)
- EXAS 2.02
- FHN 0.40
- MACD
- EXAS 0.15
- FHN -0.20
- Stochastic Oscillator
- EXAS 3.39
- FHN 15.61
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.